Identifying Drugs to Watch
We combine extensive data sets and expertise to identify potential blockbusters and therapeutic game-changers.
Drugs to Watch from Clarivate™ showcases drugs recently launched or likely to enter the market this year that are forecast to become blockbusters within five years and/or to transform treatment paradigms (blockbuster being defined by the common $1bn annual sales milestone).
Over 160 Clarivate analysts manually evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other factors. They then added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers.
Drug selection criteria
Expert analysts then added recently launched and soon-to-launch therapeutics set to significantly transform treatment paradigms, even if they are not forecast to be blockbusters within five years.
From there, we determined 11 Drugs to Watch in 2025.
Data sources and contributors
Since 2013, Clarivate has applied proprietary technologies, tools and techniques trusted by its global life sciences customers to produce the annual Drugs to Watch report.
Clarivate contributors
Related insights
Real world data reveal how diseases manifest in diverse populations
The prevalence and co-occurrence of immune-mediated inflammatory diseases (IMIDs) like inflammatory bowel disease and rheumatoid arthritis varies by race and ethnicity among U.S. adults. That’s the upshot of a retrospective…
